Alnylam Pharmaceuticals Inc. (ALNY) PT Set at $106.00 by Piper Jaffray Cos.
Alnylam Pharmaceuticals Inc. (NASDAQ:ALNY) has been given a $106.00 target price by Piper Jaffray Cos. in a report released on Thursday. The brokerage currently has a a “buy” rating on the biopharmaceutical company’s stock. Piper Jaffray Cos.’s price target would indicate a potential upside of 192.74% from the company’s current price.
Other equities research analysts have also issued research reports about the stock. Credit Suisse Group AG reaffirmed a “buy” rating on shares of Alnylam Pharmaceuticals in a research note on Sunday, June 12th. Leerink Swann reissued a “buy” rating on shares of Alnylam Pharmaceuticals in a research report on Sunday, June 12th. Cowen and Company reissued a “buy” rating on shares of Alnylam Pharmaceuticals in a research report on Sunday, June 12th. Needham & Company LLC reissued a “buy” rating on shares of Alnylam Pharmaceuticals in a research report on Monday, June 13th. Finally, FBR & Co reissued a “buy” rating on shares of Alnylam Pharmaceuticals in a research report on Friday, June 10th. Eight research analysts have rated the stock with a hold rating and nine have issued a buy rating to the company’s stock. The company currently has a consensus rating of “Buy” and a consensus target price of $86.00.
Shares of Alnylam Pharmaceuticals (NASDAQ:ALNY) traded down 7.71% during midday trading on Thursday, reaching $33.42. 4,661,933 shares of the company’s stock were exchanged. The firm has a 50-day moving average of $71.80 and a 200-day moving average of $66.24. The stock’s market capitalization is $2.86 billion. Alnylam Pharmaceuticals has a 12-month low of $33.16 and a 12-month high of $110.75.
This story is the sole property of American Banking News and it was originally published by American Banking News. If you are reading this story on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. The original version of this article is available at https://www.americanbankingnews.com/2016/10/07/alnylam-pharmaceuticals-inc-alny-pt-set-at-106-00-by-piper-jaffray-cos.html
Alnylam Pharmaceuticals (NASDAQ:ALNY) last announced its quarterly earnings results on Thursday, August 4th. The biopharmaceutical company reported ($1.05) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($1.24) by $0.19. The business had revenue of $8.70 million for the quarter, compared to analyst estimates of $8.09 million. Alnylam Pharmaceuticals had a negative net margin of 1,204.91% and a negative return on equity of 29.60%. The company’s revenue was up .2% on a year-over-year basis. During the same quarter last year, the firm earned ($0.85) EPS. Analysts anticipate that Alnylam Pharmaceuticals will post ($4.68) EPS for the current fiscal year.
In other news, CEO John Maraganore sold 30,151 shares of the business’s stock in a transaction that occurred on Wednesday, July 20th. The shares were sold at an average price of $64.69, for a total transaction of $1,950,468.19. Following the completion of the transaction, the chief executive officer now directly owns 148,465 shares of the company’s stock, valued at $9,604,200.85. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Insiders own 4.00% of the company’s stock.
Several hedge funds and other institutional investors have recently added to or reduced their stakes in ALNY. Dodge & Cox bought a new position in Alnylam Pharmaceuticals during the second quarter valued at $139,650,000. Wellington Management Group LLP boosted its position in Alnylam Pharmaceuticals by 12.1% in the first quarter. Wellington Management Group LLP now owns 11,945,607 shares of the biopharmaceutical company’s stock valued at $749,826,000 after buying an additional 1,288,123 shares during the last quarter. Bridger Management LLC bought a new position in Alnylam Pharmaceuticals during the first quarter valued at $50,041,000. Slate Path Capital LP boosted its position in Alnylam Pharmaceuticals by 56.6% in the first quarter. Slate Path Capital LP now owns 1,135,000 shares of the biopharmaceutical company’s stock valued at $71,244,000 after buying an additional 410,000 shares during the last quarter. Finally, Deerfield Management Co. bought a new position in Alnylam Pharmaceuticals during the second quarter valued at $18,645,000. 85.96% of the stock is owned by hedge funds and other institutional investors.
About Alnylam Pharmaceuticals
Alnylam Pharmaceuticals, Inc is a biopharmaceutical company. The Company is engaged in developing therapeutics based on ribonucleic acid (RNA) interference (RNAi). It is focused on the use of its N-acetylgalactosamine (GalNAc)-conjugate strategy for delivery of small interfering RNAs (siRNAs). Its pipeline of investigational RNAi therapeutics focuses in three Strategic Therapeutic Areas (STArs): Genetic Medicines; Cardio-Metabolic Disease, and Hepatic Infectious Disease.
Receive News & Ratings for Alnylam Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alnylam Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.